MA27063A1 - Derives d'acide acetique d'indane et leur utilisation en tant qu'agents therapeutiques, produits intermediaires, et leur methode de preparation - Google Patents

Derives d'acide acetique d'indane et leur utilisation en tant qu'agents therapeutiques, produits intermediaires, et leur methode de preparation

Info

Publication number
MA27063A1
MA27063A1 MA27553A MA27553A MA27063A1 MA 27063 A1 MA27063 A1 MA 27063A1 MA 27553 A MA27553 A MA 27553A MA 27553 A MA27553 A MA 27553A MA 27063 A1 MA27063 A1 MA 27063A1
Authority
MA
Morocco
Prior art keywords
preparation
acetic acid
acid derivatives
therapeutic agents
intermediate products
Prior art date
Application number
MA27553A
Other languages
English (en)
Inventor
Derek Lowe
Philip L Wickens
Mingbao Zhang
William H Bullock
Philip D G Coish
Ingo A Mugge
Andreas Stolle
Ming Wang
Yamin Wang
Chengzhi Zhang
Hai-Jun Zhang
Lei Zhu
Manami Tsutsumi
James N Livingston
Xin Ma
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA27063A1 publication Critical patent/MA27063A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C07C51/44—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation by distillation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne de nouveaux dérivés d'acide indane-acetique qui sont utiles dans le traitement de maladies telles que le diabète, l'obésité, l'hyperlipidémie et les maladies athéroscléreuses. L'invention concerne également des intermédiaires utiles dans la préparation de dérivés d'acide indane-acetique et des procédés de préparation.
MA27553A 2001-07-27 2004-02-27 Derives d'acide acetique d'indane et leur utilisation en tant qu'agents therapeutiques, produits intermediaires, et leur methode de preparation MA27063A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30850001P 2001-07-27 2001-07-27
US37304802P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
MA27063A1 true MA27063A1 (fr) 2004-12-20

Family

ID=26976280

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27553A MA27063A1 (fr) 2001-07-27 2004-02-27 Derives d'acide acetique d'indane et leur utilisation en tant qu'agents therapeutiques, produits intermediaires, et leur methode de preparation

Country Status (33)

Country Link
US (4) US6828335B2 (fr)
EP (1) EP1414809B1 (fr)
JP (1) JP4510447B2 (fr)
KR (2) KR100956898B1 (fr)
CN (1) CN100528850C (fr)
AR (1) AR036237A1 (fr)
AT (1) ATE388944T1 (fr)
AU (2) AU2002319693B2 (fr)
BR (1) BR0211502A (fr)
CA (2) CA2455620C (fr)
CO (1) CO5560561A2 (fr)
CY (1) CY1107370T1 (fr)
DE (1) DE60225561T2 (fr)
DK (1) DK1414809T3 (fr)
ES (1) ES2302825T3 (fr)
HK (2) HK1073653A1 (fr)
HR (1) HRP20040076A2 (fr)
HU (1) HUP0700105A2 (fr)
IL (3) IL159960A0 (fr)
MA (1) MA27063A1 (fr)
MX (1) MXPA04000599A (fr)
MY (1) MY139541A (fr)
NO (2) NO20040356L (fr)
NZ (1) NZ531351A (fr)
PE (1) PE20030326A1 (fr)
PL (1) PL374383A1 (fr)
PT (1) PT1414809E (fr)
RU (1) RU2314298C2 (fr)
SI (1) SI1414809T1 (fr)
SV (1) SV2003001186A (fr)
TW (2) TWI345563B (fr)
UY (1) UY27392A1 (fr)
WO (1) WO2003011842A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US20110065129A1 (en) * 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
WO2004011446A1 (fr) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Derives d'acide carboxylique d'indane, de dihydrobenzofurane et de tetrahydronaphthalene et leurs utilisations comme antidiabetiques
WO2004058174A2 (fr) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Derives d'acide acetique d'indane et leur utilisation en tant qu'agents pharmaceutiques et intermediaires, et procede de preparation correspondant
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
CA2527691C (fr) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Compose cyclique condense
WO2005110394A1 (fr) * 2004-05-19 2005-11-24 Ajinomoto Co., Inc. Agent thérapeutique pour le diabète
JP2008510696A (ja) * 2004-08-20 2008-04-10 カディラ ヘルスケア リミティド 新規抗糖尿病化合物
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
CN101410366A (zh) * 2006-03-30 2009-04-15 旭化成制药株式会社 取代双环式环状衍生物及其用途
GB0712653D0 (en) 2007-06-28 2007-08-08 Syngenta Ltd Novel herbicides
GB0717082D0 (en) 2007-09-03 2007-10-10 Syngenta Ltd Novel herbicides
CA2722102C (fr) 2008-04-28 2013-06-11 Asahi Kasei Pharma Corporation Derive d'acide phenylpropionique et son utilisation
CA2728952C (fr) * 2008-06-23 2015-06-09 Toa Eiyo Ltd. Promoteur de l'absorption percutanee et preparation transdermique l'utilisant
EP2350016A2 (fr) * 2008-10-21 2011-08-03 Metabolex Inc. Agonistes de récepteur gpr120 aryl et utilisations de ceux-ci
WO2010085811A2 (fr) * 2009-01-26 2010-07-29 Taipei Medical University Utilisation de composés ptérosine pour traiter le diabète et l'obésité
UY32442A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
US20180200230A1 (en) * 2009-06-04 2018-07-19 Dara Biosciences, Inc. Methods of treating neurodegenerative diseases using indane acetic acid derivatives which penetrate the blood brain barrier
WO2010141690A2 (fr) * 2009-06-04 2010-12-09 Dara Biosciences, Inc. Analogues d'indane, leur utilisation comme agents pharmaceutiques et leur procédé de préparation
WO2010141696A1 (fr) * 2009-06-04 2010-12-09 Dara Biosciences, Inc. Procédé de traitement préventif ou curatif du psoriasis et/ou de la maladie d'alzheimer au moyen de dérivés indane d'acide acétique
US9334266B2 (en) 2009-09-04 2016-05-10 The University Of Toledo Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
WO2012074980A2 (fr) * 2010-12-01 2012-06-07 Dara Biosciences, Inc. Procédés de traitement ou de prévention de troubles auto-immunitaires et de troubles du foie à l'aide de dérivés acides indane acétiques
EP3273964A4 (fr) * 2015-03-26 2019-01-30 T3D Therapeutics Inc. Procédés de traitement d'une maladie hépatique au moyen de dérivés d'acide indane-acétique
TWI712582B (zh) * 2015-10-14 2020-12-11 法商領先藥物公司 用來製備(5s,10s)-10-苄基-16-甲基-11,14,18-三側氧基-15,17,19-三氧雜-2,7,8-三噻基-12-氮二十一烷基-5-銨基(e)-3-羧基丙烯酸鹽的工業方法
US20180153860A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives
US20180153859A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
KR102647257B1 (ko) * 2017-07-28 2024-03-13 케모센트릭스, 인크. 면역조절제 화합물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929923A (en) * 1972-01-17 1975-12-30 Sun Research Development Process for preparation of isomers of 1-cyclohexyl-1,3,3-trimethylhydrindane
US4754043A (en) * 1985-10-03 1988-06-28 American Home Products Corporation Oxazole and thiazole naphthalenes as antiallergic agents
FR2670491B1 (fr) 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
JPH1087602A (ja) * 1996-09-09 1998-04-07 Zeria Pharmaceut Co Ltd スルホンアミド誘導体、それを含有するトロンボキサン拮抗剤及び該化合物の製造中間体
WO1999011255A1 (fr) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Regulateurs du recepteur active par les agents de proliferation des peroxysomes
KR100693771B1 (ko) 1999-04-28 2007-03-12 사노피-아벤티스 도이칠란트 게엠베하 Ｐｐａｒ 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
CZ20013833A3 (cs) 1999-04-28 2002-02-13 Aventis Pharma Deutschland Gmbh Deriváty kyselin se dvěma arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
US6417212B1 (en) * 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
AU2001284658A1 (en) * 2000-08-23 2002-03-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento

Also Published As

Publication number Publication date
IL208891A (en) 2013-02-28
PE20030326A1 (es) 2003-04-16
DE60225561T2 (de) 2009-04-23
KR100987267B1 (ko) 2010-10-12
RU2004105925A (ru) 2005-07-10
RU2314298C2 (ru) 2008-01-10
PL374383A1 (en) 2005-10-17
AU2002319693B2 (en) 2008-08-07
US20050075338A1 (en) 2005-04-07
TW201029979A (en) 2010-08-16
HUP0700105A2 (en) 2007-09-28
AR036237A1 (es) 2004-08-25
US20030216391A1 (en) 2003-11-20
EP1414809A1 (fr) 2004-05-06
ES2302825T3 (es) 2008-08-01
ATE388944T1 (de) 2008-03-15
EP1414809B1 (fr) 2008-03-12
IL208891A0 (en) 2011-01-31
WO2003011842A1 (fr) 2003-02-13
BR0211502A (pt) 2005-09-20
US7112597B2 (en) 2006-09-26
KR100956898B1 (ko) 2010-05-11
IL159960A0 (en) 2004-06-20
US7358386B2 (en) 2008-04-15
HRP20040076A2 (en) 2005-06-30
TWI345563B (en) 2011-07-21
HK1073653A1 (en) 2005-10-14
AU2008237581A1 (en) 2008-11-20
CN1558905A (zh) 2004-12-29
CA2753329A1 (fr) 2003-02-13
IL159960A (en) 2010-12-30
KR20040028950A (ko) 2004-04-03
CY1107370T1 (el) 2012-12-19
CA2455620A1 (fr) 2003-02-13
JP2005508308A (ja) 2005-03-31
KR20090125225A (ko) 2009-12-03
US20060205723A1 (en) 2006-09-14
CO5560561A2 (es) 2005-09-30
US20090047687A1 (en) 2009-02-19
UY27392A1 (es) 2003-01-31
DE60225561D1 (de) 2008-04-24
SI1414809T1 (sl) 2008-08-31
SV2003001186A (es) 2003-03-18
CN100528850C (zh) 2009-08-19
CA2455620C (fr) 2011-12-06
NO20040356L (no) 2004-03-19
NZ531351A (en) 2006-09-29
HK1098125A1 (en) 2007-07-13
NO20083411L (no) 2004-03-19
US6828335B2 (en) 2004-12-07
MXPA04000599A (es) 2005-02-17
MY139541A (en) 2009-10-30
TWI328008B (en) 2010-08-01
DK1414809T3 (da) 2008-06-23
PT1414809E (pt) 2008-06-04
JP4510447B2 (ja) 2010-07-21

Similar Documents

Publication Publication Date Title
MA27063A1 (fr) Derives d'acide acetique d'indane et leur utilisation en tant qu'agents therapeutiques, produits intermediaires, et leur methode de preparation
MY140187A (en) Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
DZ2200A1 (fr) Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase.
EP1806364A3 (fr) Nouveaux anticorps anti-igf-ir et leurs applications
EA200800375A1 (ru) Соединения и способы ингибирования экспрессии vcam-1
EA200100872A1 (ru) Композиция валдекоксиба
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
WO2004047728A3 (fr) Compositions et procedes destines au traitement de maladies de nature immune
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
IS6865A (is) Setnar alkýlamínafleiður og aðferðir við notkun þeirra
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci
TNSN99133A1 (fr) Procede perfectionne pour la preparation de bases de schiff et produits ainsi obtenus
EA200501479A1 (ru) Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
DE602005007912D1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
MA27592A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
WO2004098498A3 (fr) Derives d'acide indole acetique et leur utilisation en tant qu'agents pharmaceutiques
WO2003089418A8 (fr) Derives indane de l'acide acetique et leur utilisation comme agents pharmaceutiques
MA24682A1 (fr) Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
MX9703232A (es) Nuevos antagonistas del receptor muscarinico.
AU2002251788A1 (en) Novel compounds and uses thereof